RENIVACE Side Effects

6011834-4 | Liver Function Test Abnormal
on Dec 10, 2008 Male patient from JAPAN , 76 years of age, weighting 131.2 lb, was diagnosed with hypertension, lipids abnormal, acute myocardial infarction, percutaneous coronary intervention, stent placement, angina pectoris and was treated with Renivace (View Usage). Patient experienced the following unwanted or unexpected effects: liver function test abnormal. Renivace dosage: . During the same period patient was treated with LIVALO (View Livalo Review and Livalo Label ), ARTIST (View Artist Review and Artist Label ), BLOPRESS (View Blopress Review and Blopress Label ), PLAVIX (View Plavix Review and Plavix Label ), ASPIRIN (View Aspirin Review and Aspirin Label ).

5984170-X | Liver Function Test Abnormal
Patient was taking Renivace (View Usage). Patient had the following side effects: liver function test abnormal on Nov 26, 2008 from JAPAN Additional patient health information: Male patient , 76 years of age, weighting 131.2 lb, was diagnosed with hypertension, lipids abnormal, acute myocardial infarction, percutaneous coronary intervention, stent placement, angina pectoris and. Renivace dosage: . During the same period patient was treated with LIVALO (View Livalo Review and Livalo Label ), ARTIST (View Artist Review and Artist Label ), BLOPRESS (View Blopress Review and Blopress Label ), PLAVIX (View Plavix Review and Plavix Label ), ASPIRIN (View Aspirin Review and Aspirin Label ).

5286976-1 | Cardiac Failure, Condition Aggravated, Overdose
Adverse event was reported on Mar 13, 2007 by a Male patient taking Renivace (View Usage) (Dosage: 10 Mg Bid Po) . Location: JAPAN , 74 years of age, After Renivace was administered, patient had the following side effects: cardiac failure, condition aggravated, overdose. During the same period patient was treated with WARFARIN SODIUM (View Warfarin Sodium Review and Warfarin Sodium Label ), HALFDIGOXIN (View Halfdigoxin Review and Halfdigoxin Label ), MEVALOTIN (View Mevalotin Review and Mevalotin Label ), PLETAL (View Pletal Review and Pletal Label ). Patient was hospitalized.

5271169-4 | Eczema
on Feb 27, 2007 Female patient from JAPAN , 82 years of age, was diagnosed with cardiac failure, angina pectoris and was treated with Renivace (View Usage). Patient experienced the following unwanted or unexpected effects: eczema (What is eczema?). Renivace dosage: 2.5 Mg Qd Po. During the same period patient was treated with ITOROL (200 Mg Qd Po) (View Itorol Review and Itorol Label ), ETODOLAC (200 Mg Qd Po) (View Etodolac Review and Etodolac Label ), ACTONEL (View Actonel Review and Actonel Label ), LOXONIN /00890701/ (View Loxonin /00890701/ Review and Loxonin /00890701/ Label ), MUCOSTA (View Mucosta Review and Mucosta Label ), OSTEN (View Osten Review and Osten Label ), CELGOTIN (View Celgotin Review and Celgotin Label ).


5237047-1 | Blood Immunoglobulin E Increased, Erythema, Rash Papular
on Jan 24, 2007 Male patient from JAPAN , 65 years of age, was diagnosed with cardiac failure and was treated with Renivace (View Usage). Patient had the following side effects: blood immunoglobulin e increased, erythema, rash papular. Renivace dosage: 5 Mg Qd Po. During the same period patient was treated with NU LOTAN (50 Mg Qd Po) (View Nu Lotan Review and Nu Lotan Label ), ALDACTONE (View Aldactone Review and Aldactone Label ), LUPRAC (View Luprac Review and Luprac Label ), SPELEAR (View Spelear Review and Spelear Label ), HUSTAZOL (View Hustazol Review and Hustazol Label ), CLARITHROMYCIN (View Clarithromycin Review and Clarithromycin Label ), TAKEPRON (View Takepron Review and Takepron Label ), BAKTAR (View Baktar Review and Baktar Label ). Patient was hospitalized.

5205304-0 | Inappropriate Antidiuretic Hormone Secretion, Large Intestinal Haemorrhage, Melaena, Ulcer Haemorrhage
Patient was taking Renivace (View Usage). After Renivace was administered, patient had the following side effects: inappropriate antidiuretic hormone secretion, large intestinal haemorrhage, melaena, ulcer haemorrhage on Dec 21, 2006 from JAPAN Additional patient health information: Male patient , 93 years of age, weighting 79.37 lb, was diagnosed with cardiac failure congestive and. Renivace dosage: 5 Mg Bid Po. During the same period patient was treated with ASPIRIN (View Aspirin Review and Aspirin Label ), GASTROM (View Gastrom Review and Gastrom Label ), GASPORT D (View Gasport-d Review and Gasport-d Label ), NITRODERM (View Nitroderm Review and Nitroderm Label ), LACTEC 500 (View Lactec 500 Review and Lactec 500 Label ), SOLITA T3 (View Solita-t3 Review and Solita-t3 Label ), PURSENNID (View Pursennid Review and Pursennid Label ). Patient was hospitalized.

5201239-8 | Pharyngeal Oedema, Respiratory Disorder, Respiratory Distress, Snoring, Stridor
Adverse event was reported on Dec 18, 2006 by a Male patient taking Renivace (View Usage) (Dosage: 1.25 Mg Bid Po) was diagnosed with hypertension, stent placement, arteriogram, angina pectoris and. Location: JAPAN , 82 years of age, Patient experienced the following unwanted or unexpected effects: pharyngeal oedema, respiratory disorder, respiratory distress, snoring (What is snoring?), stridor. During the same period patient was treated with PLETAL (100 Mgb Id Po) (View Pletal Review and Pletal Label ), IOMERON 150 (295 Ml Qd Iv) (View Iomeron-150 Review and Iomeron-150 Label ), NITOROL (Df Qd Iv) (View Nitorol Review and Nitorol Label ), PANALDINE (View Panaldine Review and Panaldine Label ), ASPIRIN (View Aspirin Review and Aspirin Label ), AMLODIPINE BESYLATE (View Amlodipine Besylate Review and Amlodipine Besylate Label ), TAMBOCOR (View Tambocor Review and Tambocor Label ), NU LOTAN (View Nu-lotan Review and Nu-lotan Label ). Patient was hospitalized.

5201103-4 | Acute Myocardial Infarction, Blood Pressure Immeasurable, Cardiac Disorder, Cardio-respiratory Arrest, Cardiogenic Shock, Coronary Artery Occlusion, Coronary Artery Thrombosis, Excoriation, Gastrointestinal Haemorrhage
on Dec 20, 2006 Male patient from JAPAN , 66 years of age, was diagnosed with hypertension, gastrointestinal haemorrhage, hyperlipidaemia, coronary arterial stent insertion and was treated with Renivace (View Usage). Patient had the following side effects: acute myocardial infarction, blood pressure immeasurable, cardiac disorder, cardio-respiratory arrest, cardiogenic shock, coronary artery occlusion, coronary artery thrombosis, excoriation, gastrointestinal haemorrhage. Renivace dosage: 2.5 Mg Q Day Po. During the same period patient was treated with GASTER D (20 Mg Bid Po) (View Gaster D Review and Gaster D Label ), LIPITOR (10 Mg Q Day Po) (View Lipitor Review and Lipitor Label ), ASPIRIN (100 Mg Bid Po) (View Aspirin Review and Aspirin Label ), PLAVIX (75 Mg Q Day Po) (View Plavix Review and Plavix Label ), SIGMART (View Sigmart Review and Sigmart Label ), LUPRAC (View Luprac Review and Luprac Label ), ARTIST (View Artist Review and Artist Label ). Patient was hospitalized.

5200966-6 | Acute Myocardial Infarction, Alanine Aminotransferase Increased, Aspartate Aminotransferase Increased, Blood Creatine Phosphokinase Increased, Blood Immunoglobulin E Increased, Blood Lactate Dehydrogenase Increased, C-reactive Protein Increased, Interstitial Lung Disease, Lymphocyte Stimulation Test Positive
on Dec 15, 2006 Male patient from JAPAN , 77 years of age, weighting 141.1 lb, was diagnosed with hypertension, thrombosis prophylaxis, diabetes mellitus non-insulin-dependent, gastric ulcer and was treated with Renivace (View Usage). After Renivace was administered, patient had the following side effects: acute myocardial infarction, alanine aminotransferase increased, aspartate aminotransferase increased, blood creatine phosphokinase increased, blood immunoglobulin e increased, blood lactate dehydrogenase increased, c-reactive protein increased, interstitial lung disease, lymphocyte stimulation test positive. Renivace dosage: 5 Mg Qd Po. During the same period patient was treated with BUFFERIN /00009201/ (81 Mg Bid Po) (View Bufferin /00009201/ Review and Bufferin /00009201/ Label ), EUGLUCON (1.25 Mg Bid Po) (View Euglucon Review and Euglucon Label ), OMEPRAL (20 Mg Qd Po) (View Omepral Review and Omepral Label ), PANALDINE (100 Mg Bid Po) (View Panaldine Review and Panaldine Label ), DIOVAN /01319601/ (80 Mg Qd Po) (View Diovan /01319601/ Review and Diovan /01319601/ Label ). Patient was hospitalized.

5192164-X | Inappropriate Antidiuretic Hormone Secretion, Large Intestinal Haemorrhage, Ulcer
Patient was taking Renivace (View Usage). Patient experienced the following unwanted or unexpected effects: inappropriate antidiuretic hormone secretion, large intestinal haemorrhage, ulcer (What is ulcer?) on Dec 04, 2006 from JAPAN Additional patient health information: Male patient , 93 years of age, weighting 79.37 lb, was diagnosed with cardiac failure congestive and. Renivace dosage: 5 Mg Bid Po. During the same period patient was treated with ASPIRIN (View Aspirin Review and Aspirin Label ), GASTROM (View Gastrom Review and Gastrom Label ), GASPORT D (View Gasport-d Review and Gasport-d Label ), PURSENNID (View Pursennid Review and Pursennid Label ), NITRODERM (View Nitroderm Review and Nitroderm Label ), LACTEC 500 (View Lactec 500 Review and Lactec 500 Label ), SOLITA T3 (View Solita-t3 Review and Solita-t3 Label ). Patient was hospitalized.

5190013-7 | Bronchostenosis, Dyspnoea, Laryngeal Oedema, Pharyngeal Oedema, Respiratory Distress, Snoring, Stridor
Adverse event was reported on Dec 01, 2006 by a Male patient taking Renivace (View Usage) (Dosage: 1.25 Mg Bid Po) was diagnosed with hypertension, stent placement, arteriogram, angina pectoris and. Location: AMERICAN SAMOA , 82 years of age, Patient had the following side effects: bronchostenosis, dyspnoea, laryngeal oedema, pharyngeal oedema, respiratory distress, snoring (What is snoring?), stridor. During the same period patient was treated with PLETAL (100 Mg Bid Po) (View Pletal Review and Pletal Label ), IOMERON 150 (295 Ml Qd Iv) (View Iomeron-150 Review and Iomeron-150 Label ), NITOROL (Df Qd Iv) (View Nitorol Review and Nitorol Label ), PANALDINE (View Panaldine Review and Panaldine Label ), ASPIRIN (View Aspirin Review and Aspirin Label ), AMLODIPINE BESYLATE (View Amlodipine Besylate Review and Amlodipine Besylate Label ), TAMBOCOR (View Tambocor Review and Tambocor Label ), NU LOTAN (View Nu-lotan Review and Nu-lotan Label ). Patient was hospitalized.

5188044-6 | Blood Pressure Decreased, Cardio-respiratory Arrest, Eosinophilia, Gastrointestinal Haemorrhage, White Blood Cell Count Increased
on Nov 28, 2006 Male patient from JAPAN , 82 years of age, weighting 70.55 lb, was diagnosed with myocardial infarction and was treated with Renivace (View Usage). After Renivace was administered, patient had the following side effects: blood pressure decreased, cardio-respiratory arrest, eosinophilia, gastrointestinal haemorrhage, white blood cell count increased. Renivace dosage: 2.5 Mg Qd Po. During the same period patient was treated with ASPIRIN (View Aspirin Review and Aspirin Label ), PANALDINE (View Panaldine Review and Panaldine Label ), MAGNESIUM OXIDE (View Magnesium Oxide Review and Magnesium Oxide Label ), SIGMART (View Sigmart Review and Sigmart Label ), ARTIST (View Artist Review and Artist Label ), LUPRAC (View Luprac Review and Luprac Label ), LASIX (View Lasix Review and Lasix Label ), FLUITRAN (View Fluitran Review and Fluitran Label ).

5176426-8 | Interstitial Lung Disease
on Nov 21, 2006 Male patient from JAPAN , 77 years of age, was diagnosed with hypertension, prophylaxis, thrombosis prophylaxis and was treated with Renivace (View Usage). Patient experienced the following unwanted or unexpected effects: interstitial lung disease. Renivace dosage: 2.5 Mg Q Day Po. During the same period patient was treated with DIOVAN (80 Mg Q Day Po) (View Diovan Review and Diovan Label ), EUGLUCON (1.25 Mg Bid Po) (View Euglucon Review and Euglucon Label ), OMEPRAL (20 Mg Q Day Unk) (View Omepral Review and Omepral Label ), PANALDINE (100 Mg Bid Po) (View Panaldine Review and Panaldine Label ). Patient was hospitalized.

5175195-5 | Pharyngeal Oedema, Respiratory Distress
Patient was taking Renivace (View Usage). Patient had the following side effects: pharyngeal oedema, respiratory distress on Nov 20, 2006 from JAPAN Additional patient health information: Male patient , 82 years of age, was diagnosed with hypertension and. Renivace dosage: 1.25 Mg Bid Po. During the same period patient was treated with PANALDINE (View Panaldine Review and Panaldine Label ), LIVALO (View Livalo Review and Livalo Label ), ASPIRIN (View Aspirin Review and Aspirin Label ), AMLODIPINE BESYLATE (View Amlodipine Besylate Review and Amlodipine Besylate Label ), TAKEPRON (View Takepron Review and Takepron Label ). Patient was hospitalized.

5167489-4 | Acute Myocardial Infarction, Apparent Life Threatening Event, Blood Pressure Immeasurable, Cardiac Disorder, Cardio-respiratory Arrest, Condition Aggravated, Gastrointestinal Haemorrhage, Pyrexia, Skin Haemorrhage
Adverse event was reported on Nov 14, 2006 by a Male patient taking Renivace (View Usage) (Dosage: 2.5 Mg Q Day; Po) was diagnosed with hypertension, gastrointestinal haemorrhage, hyperlipidaemia, coronary arterial stent insertion and. Location: JAPAN , 66 years of age, After Renivace was administered, patient had the following side effects: acute myocardial infarction, apparent life threatening event, blood pressure immeasurable, cardiac disorder, cardio-respiratory arrest, condition aggravated, gastrointestinal haemorrhage, pyrexia, skin haemorrhage. During the same period patient was treated with GASTER D (20 Mg, Bid; Po) (View Gaster D Review and Gaster D Label ), LIPITOR (10 Mg Q Day; Po) (View Lipitor Review and Lipitor Label ), ASPIRIN (100 Mg Bid; Po) (View Aspirin Review and Aspirin Label ), PLAVIX (75 Mg Q Da; Po) (View Plavix Review and Plavix Label ), SIGMART (View Sigmart Review and Sigmart Label ), LUPRAC (View Luprac Review and Luprac Label ), ARTIST (View Artist Review and Artist Label ). Patient was hospitalized.

5162019-5 | Alanine Aminotransferase Increased, Aspartate Aminotransferase Increased, Blood Lactate Dehydrogenase Increased, Chills, Cholelithiasis, Gamma-glutamyltransferase Increased, Hepatic Infiltration Eosinophilic, Liver Disorder, Pyrexia
on Nov 07, 2006 Male patient from JAPAN , 73 years of age, weighting 163.1 lb, was diagnosed with myocardial infarction, gastric ulcer haemorrhage, sepsis (What is sepsis?) and was treated with Renivace (View Usage). Patient experienced the following unwanted or unexpected effects: alanine aminotransferase increased, aspartate aminotransferase increased, blood lactate dehydrogenase increased, chills, cholelithiasis, gamma-glutamyltransferase increased, hepatic infiltration eosinophilic, liver disorder, pyrexia. Renivace dosage: 2.5 Mg Bid Po. During the same period patient was treated with GASTER (20 Mg Bid Iv) (View Gaster Review and Gaster Label ), GASTER D (20 Mg Bid Po) (View Gaster D Review and Gaster D Label ), PAZUCROSS (500 Mg Bid Pa) (View Pazucross Review and Pazucross Label ), PANALDINE (100 Mg Bid Po) (View Panaldine Review and Panaldine Label ), ARTIST (5 Mg Bid Po) (View Artist Review and Artist Label ), ASPIRIN (100 Mg Bid Po) (View Aspirin Review and Aspirin Label ), SIGMART (5 Mg Bid Po) (View Sigmart Review and Sigmart Label ). Patient was hospitalized.

5162013-4 | Atrial Fibrillation, Blister, Cardiac Disorder, Cardio-respiratory Arrest, Cardiogenic Shock, Erythema, Excoriation, Gastrointestinal Haemorrhage
on Nov 06, 2006 Male patient from JAPAN , 66 years of age, was diagnosed with hypertension, gastrointestinal haemorrhage, hyperlipidaemia, coronary arterial stent insertion and was treated with Renivace (View Usage). Patient had the following side effects: atrial fibrillation (What is atrial fibrillation?), blister, cardiac disorder, cardio-respiratory arrest, cardiogenic shock, erythema, excoriation, gastrointestinal haemorrhage. Renivace dosage: 2.5 Mg Q Day Po. During the same period patient was treated with GASTER D (40 Mg Q Day Po) (View Gaster D Review and Gaster D Label ), LIPITOR (10 Mg Q Day Po) (View Lipitor Review and Lipitor Label ), ASPIRIN (200 Mg Q Day Po) (View Aspirin Review and Aspirin Label ), PLAVIX (75 Mg Q Day Po) (View Plavix Review and Plavix Label ), SIGMART (View Sigmart Review and Sigmart Label ), LUPRAC (View Luprac Review and Luprac Label ), ARTIST (View Artist Review and Artist Label ). Patient was hospitalized.

5143257-4 | Alanine Aminotransferase Increased, Aspartate Aminotransferase Increased, Blood Alkaline Phosphatase Increased, Blood Lactate Dehydrogenase Increased, Gastric Ulcer Haemorrhage, Hepatic Infiltration Eosinophilic, Liver Disorder
Patient was taking Renivace (View Usage). After Renivace was administered, patient had the following side effects: alanine aminotransferase increased, aspartate aminotransferase increased, blood alkaline phosphatase increased, blood lactate dehydrogenase increased, gastric ulcer haemorrhage, hepatic infiltration eosinophilic, liver disorder on Oct 13, 2006 from JAPAN Additional patient health information: Male patient , 73 years of age, weighting 163.1 lb, was diagnosed with hypertension, gastric ulcer, gastric ulcer haemorrhage, sepsis (What is sepsis?), angina pectoris, myocardial infarction and. Renivace dosage: 2.5 Mg Bid Po. During the same period patient was treated with FAMOTIDINE (20 Mg Bid Iv) (View Famotidine Review and Famotidine Label ), GASTER D (20 Mg Bid Po) (View Gaster D Review and Gaster D Label ), PAZUCROSS (500 Mg Bid Pa) (View Pazucross Review and Pazucross Label ), PANALDINE (100 Mg Bid Po) (View Panaldine Review and Panaldine Label ), ARTIST (5 Mg Bid Po) (View Artist Review and Artist Label ), ASPIRIN (100 Mg Bid Po) (View Aspirin Review and Aspirin Label ), SIGMART (5 Mg Bid Po) (View Sigmart Review and Sigmart Label ). Patient was hospitalized.

5141845-2 | Alanine Aminotransferase Increased, Aspartate Aminotransferase Increased, Platelet Count Decreased, Stevens-johnson Syndrome, White Blood Cell Count Decreased
Adverse event was reported on Oct 10, 2006 by a Female patient taking Renivace (View Usage) (Dosage: 5 Mg Qd Po) was diagnosed with cardiac failure, hypertension, hyperuricaemia, constipation (What is constipation?) and. Location: JAPAN , 80 years of age, Patient experienced the following unwanted or unexpected effects: alanine aminotransferase increased, aspartate aminotransferase increased, platelet count decreased, stevens-johnson syndrome, white blood cell count decreased. During the same period patient was treated with ALLOPURINOL (100 Mg Qd Po) (View Allopurinol Review and Allopurinol Label ), ADALAT (40 Mg Qd Po) (View Adalat Review and Adalat Label ), PURSENNID /00142207/ (24 Mg Prn Po) (View Pursennid /00142207/ Review and Pursennid /00142207/ Label ), LASIX (40 Mg Qd Po) (View Lasix Review and Lasix Label ). Patient was hospitalized.

5139685-3 | Blood Glucose Fluctuation, Depressed Level Of Consciousness, Intentional Overdose, Suicide Attempt
on Oct 06, 2006 Female patient from JAPAN , 43 years of age, was treated with Renivace (View Usage). Patient had the following side effects: blood glucose fluctuation, depressed level of consciousness, intentional overdose, suicide attempt. Renivace dosage: 100 Mg Once Po. Patient was hospitalized.

5132760-9 | Cardiac Failure, Condition Aggravated, Gait Disturbance, Impetigo, Nasopharyngitis, Pemphigoid, Spinal Compression Fracture
on Sep 28, 2006 Male patient from JAPAN , 75 years of age, weighting 90.39 lb, was diagnosed with cardiac failure and was treated with Renivace (View Usage). After Renivace was administered, patient had the following side effects: cardiac failure, condition aggravated, gait disturbance, impetigo (What is impetigo?), nasopharyngitis, pemphigoid, spinal compression fracture. Renivace dosage: 2.5 Mg Bid Po. During the same period patient was treated with AMLODIN (View Amlodin Review and Amlodin Label ), LASIX (View Lasix Review and Lasix Label ), GASTER D (View Gaster D Review and Gaster D Label ), CLARITIN (View Claritin Review and Claritin Label ), FEXOFENADINE (View Fexofenadine Review and Fexofenadine Label ), DIFLUPREDNATE (View Difluprednate Review and Difluprednate Label ). Patient was hospitalized.

5131746-8 | Depressed Level Of Consciousness, Hypoglycaemia
Patient was taking Renivace (View Usage). Patient experienced the following unwanted or unexpected effects: depressed level of consciousness, hypoglycaemia on Sep 29, 2006 from JAPAN Additional patient health information: Male patient , 75 years of age, . Renivace dosage: 7.5 Mh Q Day Po.

5114872-9 | Nephritis Interstitial, Renal Failure
Adverse event was reported on Sep 05, 2006 by a Female patient taking Renivace (View Usage) (Dosage: 5 Mg Qd Po) was diagnosed with renal hypertension and. Location: JAPAN , child 9 years of age, weighting 55.12 lb, Patient had the following side effects: nephritis interstitial, renal failure. During the same period patient was treated with PASETOCIN /0024901/ (View Pasetocin /0024901/ Review and Pasetocin /0024901/ Label ), ADALAT (View Adalat Review and Adalat Label ). Patient was hospitalized.

5102516-1 | Alanine Aminotransferase Increased, Aspartate Aminotransferase Increased, Blood Alkaline Phosphatase Increased, Blood Bilirubin Increased, Blood Lactate Dehydrogenase Increased, Gamma-glutamyltransferase Increased, Liver Disorder, Lymphocyte Stimulation Test Positive
on Aug 23, 2006 Male patient from JAPAN , 70 years of age, weighting 149.9 lb, was diagnosed with hypertension, angina pectoris, coronary arterial stent insertion, hyperlipidaemia, hypertonia and was treated with Renivace (View Usage). After Renivace was administered, patient had the following side effects: alanine aminotransferase increased, aspartate aminotransferase increased, blood alkaline phosphatase increased, blood bilirubin increased, blood lactate dehydrogenase increased, gamma-glutamyltransferase increased, liver disorder, lymphocyte stimulation test positive. Renivace dosage: 5 Mg Q Day Po. During the same period patient was treated with PANALDINE (100 Mg Bid Po) (View Panaldine Review and Panaldine Label ), LIVALO (2 Mg Q Day Po) (View Livalo Review and Livalo Label ), SIGMART (5 Mg Tid Po) (View Sigmart Review and Sigmart Label ), CALBLOCK (16 Mg Q Day Po) (View Calblock Review and Calblock Label ), ARTIST (2.5 Mg Bid Po) (View Artist Review and Artist Label ). Patient was hospitalized.

5085260-9 | Alanine Aminotransferase Increased, Aspartate Aminotransferase Increased, Blood Alkaline Phosphatase Increased, Blood Bilirubin Increased, Gamma-glutamyltransferase Increased, Liver Disorder, Lymphocyte Stimulation Test, Lymphocyte Stimulation Test Positive
on Jul 31, 2006 Male patient from ALBANIA , 70 years of age, weighting 149.9 lb, was diagnosed with hypertension, angina pectoris, coronary arterial stent insertion, hyperlipidaemia, hypertonia and was treated with Renivace (View Usage). Patient experienced the following unwanted or unexpected effects: alanine aminotransferase increased, aspartate aminotransferase increased, blood alkaline phosphatase increased, blood bilirubin increased, gamma-glutamyltransferase increased, liver disorder, lymphocyte stimulation test, lymphocyte stimulation test positive. Renivace dosage: 5 Mg Q Day Po. During the same period patient was treated with PANALDINE (100 Mg Bid Po) (View Panaldine Review and Panaldine Label ), LIVALO (2 Mg Q Day Po) (View Livalo Review and Livalo Label ), SIGMART (5 Mg Tid Po) (View Sigmart Review and Sigmart Label ), CALBLOCK (16 Mg Q Day Po) (View Calblock Review and Calblock Label ), ARTIST (2.5 Mg Bid Po) (View Artist Review and Artist Label ). Patient was hospitalized.

5062577-5 | Angioneurotic Oedema, Depressed Level Of Consciousness, Dyspnoea, Laboratory Test Abnormal, Pharyngeal Stenosis, Pharyngolaryngeal Pain, Respiratory Arrest, Tonsillar Disorder
Patient was taking Renivace (View Usage). Patient had the following side effects: angioneurotic oedema, depressed level of consciousness, dyspnoea, laboratory test abnormal, pharyngeal stenosis, pharyngolaryngeal pain, respiratory arrest, tonsillar disorder on Jul 06, 2006 from JAPAN Additional patient health information: Female patient , 79 years of age, weighting 132.3 lb, was diagnosed with hypertension and. Renivace dosage: 5 Mg Qam Po. During the same period patient was treated with UNIPHYL (View Uniphyl Review and Uniphyl Label ), LORAZEPAM (View Lorazepam Review and Lorazepam Label ), SEPAMIT R (View Sepamit-r Review and Sepamit-r Label ), ONION/PRANKULAST HYDRATE (View Onion/prankulast Hydrate Review and Onion/prankulast Hydrate Label ), GASTER D (View Gaster D Review and Gaster D Label ), LASIX /00032601/ (View Lasix /00032601/ Review and Lasix /00032601/ Label ), ZYRTEC (View Zyrtec Review and Zyrtec Label ), FLUTIDE (View Flutide Review and Flutide Label ). Patient was hospitalized.

5050441-7 | Alanine Aminotransferase Increased, Angioneurotic Oedema, Aspartate Aminotransferase Increased, Blood Alkaline Phosphatase Increased, Blood Lactate Dehydrogenase Increased, Disease Recurrence, Dysphonia, Eosinophil Percentage Decreased, Face Oedema
Adverse event was reported on Jun 21, 2006 by a Male patient taking Renivace (View Usage) (Dosage: 5 Mg Qd Po) was diagnosed with hypertension and. Location: JAPAN , 53 years of age, After Renivace was administered, patient had the following side effects: alanine aminotransferase increased, angioneurotic oedema, aspartate aminotransferase increased, blood alkaline phosphatase increased, blood lactate dehydrogenase increased, disease recurrence, dysphonia, eosinophil percentage decreased, face oedema. During the same period patient was treated with ASPIRIN (View Aspirin Review and Aspirin Label ), MARZULENE S (View Marzulene S Review and Marzulene S Label ), DILTIAZEM HCL (View Diltiazem Hcl Review and Diltiazem Hcl Label ). Patient was hospitalized.

5050368-0 | Angioneurotic Oedema, Depressed Level Of Consciousness, Dysarthria, Laboratory Test Abnormal, Oropharyngeal Swelling, Pharyngeal Stenosis, Pharyngolaryngeal Pain, Respiratory Arrest
on Jun 21, 2006 Female patient from JAPAN , 79 years of age, weighting 132.3 lb, was diagnosed with hypertension and was treated with Renivace (View Usage). Patient experienced the following unwanted or unexpected effects: angioneurotic oedema, depressed level of consciousness, dysarthria, laboratory test abnormal, oropharyngeal swelling, pharyngeal stenosis, pharyngolaryngeal pain, respiratory arrest. Renivace dosage: 5 Mg Qam Po. During the same period patient was treated with UNIPHYL (View Uniphyl Review and Uniphyl Label ), LORAZEPAM (View Lorazepam Review and Lorazepam Label ), SEPAMIT R (View Sepamit-r Review and Sepamit-r Label ), ONION/PRANKULAST HYDRATE (View Onion/prankulast Hydrate Review and Onion/prankulast Hydrate Label ), GASTER D (View Gaster D Review and Gaster D Label ), LASIX (View Lasix Review and Lasix Label ), ZYRTEC (View Zyrtec Review and Zyrtec Label ), FLUTIDE (View Flutide Review and Flutide Label ). Patient was hospitalized.

5031870-4 | Anaemia, Gastrointestinal Haemorrhage
on May 31, 2006 Male patient from JAPAN , 75 years of age, was treated with Renivace (View Usage). Patient had the following side effects: anaemia, gastrointestinal haemorrhage. Renivace dosage: 5 Mg Q Day Po. During the same period patient was treated with ASPIRIN (View Aspirin Review and Aspirin Label ), DEPAS (View Depas Review and Depas Label ), DIOVAN /01319601/ (View Diovan /01319601/ Review and Diovan /01319601/ Label ), HERBESSER (View Herbesser Review and Herbesser Label ), SELBEX (View Selbex Review and Selbex Label ), SIGMART (View Sigmart Review and Sigmart Label ), ZANTAC (View Zantac Review and Zantac Label ), ALLOPURINOL (View Allopurinol Review and Allopurinol Label ). Patient was hospitalized.

5002656-1 | Anxiety, Back Pain, Blood Pressure Fluctuation, Blood Pressure Systolic Increased, Dysstasia, Fall, Hypotension, Lacunar Infarction, Mitral Valve Incompetence
Patient was taking Renivace (View Usage). After Renivace was administered, patient had the following side effects: anxiety (What is anxiety?), back pain (What is back pain?), blood pressure fluctuation, blood pressure systolic increased, dysstasia, fall (What is fall?), hypotension, lacunar infarction, mitral valve incompetence on Apr 24, 2006 from JAPAN Additional patient health information: Female patient , 72 years of age, weighting 97.00 lb, was diagnosed with hypertension, depressive symptom and. Renivace dosage: 2.5 Mg Q Day Po. During the same period patient was treated with DEPROMEL /00615201/ (50 Mg Q Day Po) (View Depromel /00615201/ Review and Depromel /00615201/ Label ), MYONAL (50 Mg Q Day Po) (View Myonal Review and Myonal Label ), GASMOTIN (15 Mg Q Day Po) (View Gasmotin Review and Gasmotin Label ), PAXIL (Df Po) (View Paxil Review and Paxil Label ), MEILAX (1 Mg Q Day Po) (View Meilax Review and Meilax Label ), HYPEN (View Hypen Review and Hypen Label ). Patient was hospitalized.

5002614-7 | Blood Sodium Decreased, Bradycardia, Chest Discomfort, Cholelithiasis, Condition Aggravated, Haemodialysis, Hepatic Function Abnormal, Hyperkalaemia, Hypotension
Adverse event was reported on Apr 24, 2006 by a Female patient taking Renivace (View Usage) (Dosage: 5 Mg Bid Po) was diagnosed with hypertension, arthralgia and. Location: JAPAN , 76 years of age, weighting 88.18 lb, Patient experienced the following unwanted or unexpected effects: blood sodium decreased, bradycardia, chest discomfort, cholelithiasis, condition aggravated, haemodialysis, hepatic function abnormal, hyperkalaemia, hypotension. During the same period patient was treated with MICARDIS (40 Mg Bid Po) (View Micardis Review and Micardis Label ), MAINROL (5 Mg Bid Po) (View Mainrol Review and Mainrol Label ), MERICUT (50 Mg Q Day Rc) (View Mericut Review and Mericut Label ), LANDEL (View Landel Review and Landel Label ), AMARYL (View Amaryl Review and Amaryl Label ), CARDENALIN (View Cardenalin Review and Cardenalin Label ), LASIX /00032601/ (View Lasix /00032601/ Review and Lasix /00032601/ Label ), LUDIOMIL /00331902/ (View Ludiomil /00331902/ Review and Ludiomil /00331902/ Label ). Patient was hospitalized.

4996591-2 | Blood Pressure Diastolic Decreased, Blood Pressure Systolic Increased, Intentional Overdose, Suicide Attempt
on Apr 19, 2006 Male patient from JAPAN , 48 years of age, weighting 158.7 lb, was treated with Renivace (View Usage). Patient had the following side effects: blood pressure diastolic decreased, blood pressure systolic increased, intentional overdose, suicide attempt. Renivace dosage: 150 Mg Once Po. Patient was hospitalized.

4989346-6 | Blood Pressure Systolic Increased, Bradycardia, Dysstasia, Fall, Hypotension
on Apr 10, 2006 Female patient from JAPAN , 72 years of age, was diagnosed with hypertension, depressive symptom and was treated with Renivace (View Usage). After Renivace was administered, patient had the following side effects: blood pressure systolic increased, bradycardia, dysstasia, fall (What is fall?), hypotension. Renivace dosage: 2.5 Mg Q Day Po. During the same period patient was treated with DEPROMEL (Df Po) (View Depromel Review and Depromel Label ), PAXIL (View Paxil Review and Paxil Label ), MEILAX (View Meilax Review and Meilax Label ). Patient was hospitalized.

4984541-4 | Accidental Overdose, No Adverse Effect
Patient was taking Renivace (View Usage). Patient experienced the following unwanted or unexpected effects: accidental overdose, no adverse effect on Apr 05, 2006 from JAPAN Additional patient health information: Female patient , weighting 22.05 lb, . Renivace dosage: 1.25 Mg Once Po.

4984370-1 | Blood Aldosterone Decreased, Blood Alkaline Phosphatase Increased, Blood Creatinine Increased, Blood Lactate Dehydrogenase Increased, Blood Urea Increased, Carcinoembryonic Antigen Increased, Condition Aggravated, Creatinine Renal Clearance Decreased, Eosinophil Percentage Increased
Adverse event was reported on Apr 04, 2006 by a Male patient taking Renivace (View Usage) (Dosage: 5 Mg Q Day Po) was diagnosed with hypertension and. Location: JAPAN , 77 years of age, Patient had the following side effects: blood aldosterone decreased, blood alkaline phosphatase increased, blood creatinine increased, blood lactate dehydrogenase increased, blood urea increased, carcinoembryonic antigen increased, condition aggravated, creatinine renal clearance decreased, eosinophil percentage increased. During the same period patient was treated with DILTIAZEM HCL (View Diltiazem Hcl Review and Diltiazem Hcl Label ), ASPIRIN (View Aspirin Review and Aspirin Label ), MAGNESIUM OXIDE (View Magnesium Oxide Review and Magnesium Oxide Label ), FORSENID /00571901/ (View Forsenid /00571901/ Review and Forsenid /00571901/ Label ), GASTER D (View Gaster D Review and Gaster D Label ), ANTIBIOTIC (View Antibiotic Review and Antibiotic Label ), PHYSIOLOGICAL SALINE (View Physiological Saline Review and Physiological Saline Label ).

4984251-3 | Blood Sodium Decreased, Bradycardia, Chest Discomfort, Condition Aggravated, Dialysis, Haemodialysis, Hepatic Function Abnormal, Hyperkalaemia, Overdose
on Apr 03, 2006 Female patient from JAPAN , 76 years of age, weighting 88.18 lb, was diagnosed with hypertension, arthralgia and was treated with Renivace (View Usage). After Renivace was administered, patient had the following side effects: blood sodium decreased, bradycardia, chest discomfort, condition aggravated, dialysis (What is dialysis?), haemodialysis, hepatic function abnormal, hyperkalaemia, overdose. Renivace dosage: 5 Mg Bid Po. During the same period patient was treated with MICARDIS (40 Mg Bid Po) (View Micardis Review and Micardis Label ), LANDEL (View Landel Review and Landel Label ), AMARYL (View Amaryl Review and Amaryl Label ), CARDENALIN (View Cardenalin Review and Cardenalin Label ), MAINROL (5 Mg Bid Po) (View Mainrol Review and Mainrol Label ), MERICUT (50 Mg Q Day Rc) (View Mericut Review and Mericut Label ), LASIX /00032601/ (View Lasix /00032601/ Review and Lasix /00032601/ Label ), LUDIOMIL /00331902/ (View Ludiomil /00331902/ Review and Ludiomil /00331902/ Label ). Patient was hospitalized.

4984250-1 | Asthenia, Blood Creatinine Increased, Blood Glucose Increased, Blood Insulin Increased, Blood Pressure Systolic Increased, Blood Urea Increased, Creatinine Renal Clearance Decreased, Discomfort, Femoral Neck Fracture
on Apr 03, 2006 Female patient from JAPAN , 82 years of age, weighting 77.16 lb, was diagnosed with hypertension, angina pectoris and was treated with Renivace (View Usage). Patient experienced the following unwanted or unexpected effects: asthenia, blood creatinine increased, blood glucose increased, blood insulin increased, blood pressure systolic increased, blood urea increased, creatinine renal clearance decreased, discomfort, femoral neck fracture. Renivace dosage: 10 Mg Qd Po. During the same period patient was treated with ARTIST (10 Mg Qd Po) (View Artist Review and Artist Label ), ASPIRIN (100 Mg Qd Po) (View Aspirin Review and Aspirin Label ), NITOROL R (View Nitorol R Review and Nitorol R Label ), MUCOSTA (View Mucosta Review and Mucosta Label ), GLUCOSE (View Glucose Review and Glucose Label ), HYDROCORTISONE SODIUM SUCCINATE (View Hydrocortisone Sodium Succinate Review and Hydrocortisone Sodium Succinate Label ), NORVASC (View Norvasc Review and Norvasc Label ), DIART (View Diart Review and Diart Label ). Patient was hospitalized.

4983277-3 | Overdose, Suicide Attempt
Patient was taking Renivace (View Usage). Patient had the following side effects: overdose, suicide attempt on Apr 03, 2006 from JAPAN Additional patient health information: Male patient , 48 years of age, weighting 132.3 lb, . Renivace dosage: 150 Mg Once Po.

4978416-4 | Aspartate Aminotransferase Decreased, Blood Chloride Decreased, Blood Cholesterol Increased, Blood Creatinine Decreased, Blood Lactate Dehydrogenase Increased, Blood Potassium Decreased, Blood Pressure Diastolic Decreased, Blood Sodium Decreased, Blood Urine Present
Adverse event was reported on Mar 29, 2006 by a Male patient taking Renivace (View Usage) (Dosage: 1 Df Q Day Po) was diagnosed with glomerulonephritis membranous and. Location: JAPAN , 56 years of age, weighting 103.6 lb, After Renivace was administered, patient had the following side effects: aspartate aminotransferase decreased, blood chloride decreased, blood cholesterol increased, blood creatinine decreased, blood lactate dehydrogenase increased, blood potassium decreased, blood pressure diastolic decreased, blood sodium decreased, blood urine present. During the same period patient was treated with MEDROL (6 Df Q Day Po) (View Medrol Review and Medrol Label ), SYNTHEPEN (800000 Mu Q Day Po) (View Synthepen Review and Synthepen Label ), PERSANTIN (6 Df Q Day Po) (View Persantin Review and Persantin Label ), GLYCYRON (3 Df Q Day Po) (View Glycyron Review and Glycyron Label ), ASPARA K (1800 Mg Q Day Po) (View Aspara K Review and Aspara K Label ), GASLON N (1 Df Q Day Po) (View Gaslon N Review and Gaslon N Label ), GASTER (40 Mg Q Day Po) (View Gaster Review and Gaster Label ), BREDININ (6 Df Q Day Po) (View Bredinin Review and Bredinin Label ). Patient was hospitalized.

4971767-9 | Anorexia, Blood Lactate Dehydrogenase Increased, Bronchitis, Dysphagia, Hyperlipidaemia
on Mar 22, 2006 Female patient from JAPAN , 73 years of age, weighting 105.8 lb, was diagnosed with cardiac failure, bronchitis (What is bronchitis?) and was treated with Renivace (View Usage). Patient experienced the following unwanted or unexpected effects: anorexia, blood lactate dehydrogenase increased, bronchitis (What is bronchitis?), dysphagia, hyperlipidaemia. Renivace dosage: 2.5 Mg Q Day Po. During the same period patient was treated with FLOMOX (100 Mg Tid Po) (View Flomox Review and Flomox Label ), ALDACTONE (View Aldactone Review and Aldactone Label ), WARFARIN SODIUM (View Warfarin Sodium Review and Warfarin Sodium Label ), LANIRAPID (View Lanirapid Review and Lanirapid Label ).

4971762-X | Blood Sodium Decreased, Bradycardia, Chest Discomfort, Condition Aggravated, Dialysis, Haemodialysis, Hepatic Function Abnormal, Hyperkalaemia
on Mar 22, 2006 Female patient from JAPAN , 76 years of age, weighting 88.18 lb, was diagnosed with hypertension, arthralgia and was treated with Renivace (View Usage). Patient had the following side effects: blood sodium decreased, bradycardia, chest discomfort, condition aggravated, dialysis (What is dialysis?), haemodialysis, hepatic function abnormal, hyperkalaemia. Renivace dosage: 5 Mg Bid Po. During the same period patient was treated with MICARDIS (40 Mg Bid Po) (View Micardis Review and Micardis Label ), LANDEL (View Landel Review and Landel Label ), AMARYL (View Amaryl Review and Amaryl Label ), CARDENALIN (View Cardenalin Review and Cardenalin Label ), MAINROL (5 Mg Bid Po) (View Mainrol Review and Mainrol Label ), MERICUT (50 Mg Q Day Rc) (View Mericut Review and Mericut Label ), LASIX (View Lasix Review and Lasix Label ), LUDIOMIL (View Ludiomil Review and Ludiomil Label ). Patient was hospitalized.

4963768-1 | Overdose, Suicide Attempt
Patient was taking Renivace (View Usage). After Renivace was administered, patient had the following side effects: overdose, suicide attempt on Mar 14, 2006 from JAPAN Additional patient health information: Male patient , 48 years of age, . Renivace dosage: 150 Mg Once Po.

4963656-0 | Blood Creatinine Increased, Blood Glucose Increased, Blood Insulin Increased, Blood Pressure Diastolic Decreased, Blood Pressure Systolic Increased, Blood Urea Increased, Body Temperature Decreased, Creatinine Renal Clearance Decreased, Depressed Level Of Consciousness
Adverse event was reported on Mar 14, 2006 by a Female patient taking Renivace (View Usage) (Dosage: 10 Mg Qd Po) was diagnosed with hypertension, angina pectoris and. Location: JAPAN , 82 years of age, weighting 77.16 lb, Patient experienced the following unwanted or unexpected effects: blood creatinine increased, blood glucose increased, blood insulin increased, blood pressure diastolic decreased, blood pressure systolic increased, blood urea increased, body temperature decreased, creatinine renal clearance decreased, depressed level of consciousness. During the same period patient was treated with ARTIST (10 Mg Qd Po) (View Artist Review and Artist Label ), ASPIRIN (100 Mg Qd Po) (View Aspirin Review and Aspirin Label ), NORVASC (View Norvasc Review and Norvasc Label ), DIART (View Diart Review and Diart Label ), NITOROL R (View Nitorol R Review and Nitorol R Label ), MUCOSTA (View Mucosta Review and Mucosta Label ), FLUCOSE (View Flucose Review and Flucose Label ), HYDROCORTISONE SODIUM SUCCINATE (View Hydrocortisone Sodium Succinate Review and Hydrocortisone Sodium Succinate Label ). Patient was hospitalized.

4963544-X | Aspartate Aminotransferase Decreased, Blood Chloride Decreased, Blood Cholesterol Increased, Blood Creatinine Decreased, Blood Lactate Dehydrogenase Increased, Blood Potassium Decreased, Blood Pressure Diastolic Decreased, Blood Sodium Decreased, Blood Urine Present
on Mar 14, 2006 Male patient from JAPAN , 56 years of age, weighting 103.6 lb, was diagnosed with glomerulonephritis membranous and was treated with Renivace (View Usage). Patient had the following side effects: aspartate aminotransferase decreased, blood chloride decreased, blood cholesterol increased, blood creatinine decreased, blood lactate dehydrogenase increased, blood potassium decreased, blood pressure diastolic decreased, blood sodium decreased, blood urine present. Renivace dosage: 1 Df Q Day Po. During the same period patient was treated with BREDININ (View Bredinin Review and Bredinin Label ), SYNTHEPEN (View Synthepen Review and Synthepen Label ), GASTER (View Gaster Review and Gaster Label ), GASLON N (View Gaslon N Review and Gaslon N Label ), GLYCYRON (View Glycyron Review and Glycyron Label ), ASPARA K (View Aspara K Review and Aspara K Label ), PERSANTIN (View Persantin Review and Persantin Label ), MEDROL (View Medrol Review and Medrol Label ). Patient was hospitalized.

4954551-1 | Anorexia, Cough, Dysphagia
on Mar 03, 2006 Female patient from JAPAN , 70 years of age, was diagnosed with cardiac failure and was treated with Renivace (View Usage). After Renivace was administered, patient had the following side effects: anorexia, cough, dysphagia. Renivace dosage: 2.5 Mg Q Day Po. During the same period patient was treated with ALDACTONE (View Aldactone Review and Aldactone Label ), DIGOXIN (View Digoxin Review and Digoxin Label ), WARFARIN SODIUM (View Warfarin Sodium Review and Warfarin Sodium Label ), MUCODYNE (View Mucodyne Review and Mucodyne Label ).

4952120-0 | Blood Aldosterone Decreased, Blood Alkaline Phosphatase Increased, Blood Creatinine Increased, Blood Lactate Dehydrogenase Increased, Blood Urea Increased, Creatinine Renal Clearance Decreased, Eosinophil Percentage Increased, Hyperkalaemia, Hyponatraemia
Patient was taking Renivace (View Usage). Patient experienced the following unwanted or unexpected effects: blood aldosterone decreased, blood alkaline phosphatase increased, blood creatinine increased, blood lactate dehydrogenase increased, blood urea increased, creatinine renal clearance decreased, eosinophil percentage increased, hyperkalaemia, hyponatraemia on Mar 02, 2006 from JAPAN Additional patient health information: Male patient , 77 years of age, was diagnosed with hypertension and. Renivace dosage: 5 Mg Q Day Po. During the same period patient was treated with DILTIAZEM HCL (View Diltiazem Hcl Review and Diltiazem Hcl Label ), ASPIRIN (View Aspirin Review and Aspirin Label ), MAGNESIUM OXIDE (View Magnesium Oxide Review and Magnesium Oxide Label ), FORSENID (View Forsenid Review and Forsenid Label ), GASTER D (View Gaster D Review and Gaster D Label ), ANTIBIOTIC (View Antibiotic Review and Antibiotic Label ), PHYSIOLOGICAL SALINE (View Physiological Saline Review and Physiological Saline Label ).

4943823-2 | Asthenia, Blood Glucose Increased, Blood Insulin Increased, Cold Sweat, Discomfort, Hypoglycaemia, Tremor
Adverse event was reported on Feb 22, 2006 by a Female patient taking Renivace (View Usage) (Dosage: 10 Mg Qd Po) was diagnosed with hypertension, angina pectoris and. Location: JAPAN , 82 years of age, weighting 77.16 lb, Patient had the following side effects: asthenia, blood glucose increased, blood insulin increased, cold sweat, discomfort, hypoglycaemia, tremor. During the same period patient was treated with ARTIST (10 Mg Qd Po) (View Artist Review and Artist Label ), ASPIRIN (100 Mg Qd Po) (View Aspirin Review and Aspirin Label ), NORVASC /00972401/ (View Norvasc /00972401/ Review and Norvasc /00972401/ Label ), DIART (View Diart Review and Diart Label ), NITOROL R (View Nitorol R Review and Nitorol R Label ), MUCOSTA (View Mucosta Review and Mucosta Label ), GLUCOSE (View Glucose Review and Glucose Label ), HYDROCORTISONE SODIUM SUCCINATE (View Hydrocortisone Sodium Succinate Review and Hydrocortisone Sodium Succinate Label ). Patient was hospitalized.

4921525-6 | Abnormal Behaviour, Atrial Fibrillation, Bradycardia, Cognitive Disorder, Depressed Level Of Consciousness, Disease Recurrence
on Feb 03, 2006 Male patient from JAPAN , 86 years of age, was diagnosed with abnormal behaviour, irritability and was treated with Renivace (View Usage). After Renivace was administered, patient had the following side effects: abnormal behaviour, atrial fibrillation (What is atrial fibrillation?), bradycardia, cognitive disorder, depressed level of consciousness, disease recurrence. Renivace dosage: Df Po. During the same period patient was treated with CARBAMAZEPINE (300 Mg Po) (View Carbamazepine Review and Carbamazepine Label ), FUROSEMIDE (Df Po) (View Furosemide Review and Furosemide Label ), WARFARIN POTASSIUM (Df Po) (View Warfarin Potassium Review and Warfarin Potassium Label ), FAMOTIDINE (Df Po) (View Famotidine Review and Famotidine Label ), TOCOPHEROL CONCENTRATE CAP (Df Po) (View Tocopherol Concentrate Cap Review and Tocopherol Concentrate Cap Label ), REBAMIPIDE (Df Po) (View Rebamipide Review and Rebamipide Label ).

4897225-8 | Abnormal Behaviour, Atrial Fibrillation, Bradycardia, Cholestasis, Convulsion, Dementia, Depressed Level Of Consciousness
on Jan 11, 2006 Male patient from JAPAN , 86 years of age, was diagnosed with abnormal behaviour, irritability and was treated with Renivace (View Usage). Patient experienced the following unwanted or unexpected effects: abnormal behaviour, atrial fibrillation (What is atrial fibrillation?), bradycardia, cholestasis, convulsion, dementia (What is dementia?), depressed level of consciousness. Renivace dosage: Df Unk Po. During the same period patient was treated with CARBAMAZEPINE (Df Unk Po) (View Carbamazepine Review and Carbamazepine Label ), FUROSEMIDE (View Furosemide Review and Furosemide Label ), WARFARIN POTASSIUM (View Warfarin Potassium Review and Warfarin Potassium Label ), FAMOTIDINE (View Famotidine Review and Famotidine Label ), TOCOPHEROL NICOTAINATE (View Tocopherol Nicotainate Review and Tocopherol Nicotainate Label ), REBAMIPIDE (View Rebamipide Review and Rebamipide Label ).

4892093-2 | Cerebral Infarction, Purpura, Thrombocytopenia
Patient was taking Renivace (View Usage). Patient had the following side effects: cerebral infarction, purpura, thrombocytopenia on Jan 06, 2006 from JAPAN Additional patient health information: Female patient , 92 years of age, was diagnosed with hypertension, neurogenic bladder, gastritis and. Renivace dosage: 2.5 Mg Bid Po. During the same period patient was treated with POLLAKISU (2 Mg Q Day Po) (View Pollakisu Review and Pollakisu Label ), POSTININ (Df) (View Postinin Review and Postinin Label ), NORVASC (5 Mg Q Day Po) (View Norvasc Review and Norvasc Label ), GASTER D (20 Mg Qd Po) (View Gaster D Review and Gaster D Label ), OPALMON (View Opalmon Review and Opalmon Label ), GLUCONSAN K (View Gluconsan K Review and Gluconsan K Label ), MARZULENE S (View Marzulene S Review and Marzulene S Label ), MUCODYNE (View Mucodyne Review and Mucodyne Label ). Patient was hospitalized.